Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)

Next Previous
X
Search
Trial Profile

Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Mannitol
  • Indications Arteriovenous malformations; Meningioma; Necrosis; Neurilemmoma; Trigeminal neuralgia
  • Focus Therapeutic Use
  • Acronyms LIBERTI
  • Sponsors Norton Healthcare Limited

    • Most Recent Events

    • 01 Dec 2022 Results assessing the safety and efficacy of a single low-dose targeted bevacizumab infusion after blood-brain barrier disruption (BBBD) in adult patients with steroid-refractory brain radiation necrosis, published in the Journal of Neurosurgery.
    • 25 Jun 2021 Status changed from active, no longer recruiting to completed.
    • 09 Oct 2017 Planned number of patients changed from 15 to 10.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top